替诺福韦与恩替卡韦在乙肝相关肝动脉栓塞化疗术中抗病毒临床疗效
Clinical Efficacy of Tenofovir and Entecavir as Antiviral Agents in Hepatitis B Virus-Associated Transarterial Chemoembolization
DOI: 10.12677/JCPM.2024.31003, PDF,   
作者: 郭鑫杰, 王海久*：青海大学附属医院肝胆胰外科，青海 西宁
关键词: 替诺福韦；恩替卡韦；肝动脉栓塞化疗术；抗病毒；Tenofovir； Entecavir； Transarterial Chemoembolization； Antiviral
摘要: 乙型肝炎病毒(HBV)是肝癌的高危致病因素，在全球范围内，约54%患者患有乙型病毒性肝炎，在我国约80%肝癌患者患有乙型病毒性肝炎。因此，对于肝癌的治疗，在常规治疗方式的基础上，结合抗病毒治疗，对于阻止病毒复制、延缓肝硬化进程以及促进预后具有积极意义。替诺福韦和恩替卡韦在乙肝患者中被广泛应用，虽然两种药物短期效果较好，但其临床应用的具体疗效仍是讨论重点。本文就替诺福韦与恩替卡韦对HBV相关肝动脉栓塞化疗术抗病毒的临床疗效，结合既往研究进行综述。
Abstract: Hepatitis B virus (HBV) is a high-risk cause of hepatocellular carcinoma; worldwide, 54% of patients have viral hepatitis B. In China, almost 80% of patients with hepatocellular carcinoma also have vi-ral hepatitis B. Therefore, combining antiviral therapy with conventional treatment modalities for hepatocellular carcinoma is of positive significance in stopping viral replication, slowing down the progression of cirrhosis and promoting prognosis. Patients with hepatitis B are commonly treated with entecavir and tenofovir. Even if both medications have superior short-term effects, there is still debate over the precise clinical application’s usefulness. In light of earlier research, this paper compares the clinical effectiveness of entecavir vs. tenofovir for antiviral therapy in conjunction with chemotherapy for HBV-related hepatic artery embolization.
文章引用：郭鑫杰, 王海久. 替诺福韦与恩替卡韦在乙肝相关肝动脉栓塞化疗术中抗病毒临床疗效[J]. 临床个性化医学, 2024, 3(1): 14-17. https://doi.org/10.12677/JCPM.2024.31003

参考文献

[1] 陈建国, 张永辉, 陆建华, 陆玲玲, 陈海珍, 邵晶晶, 王高仁. 中国肝癌预防与筛检工作实践及防控挑战[J]. 中国肿瘤, 2023, 32(11): 836-847.
[2] 刘德, 陈培培, 娄培安, 乔程, 李婷, 张盼, 江宜雪, 董宗美, 朱璇, 俞浩. 1990-2019年江苏省乙型肝炎病毒感染相关肝癌发病和死亡趋势分析[J]. 中华疾病控制杂志, 2023, 27(10): 1221-1227.
[3] Zhou, Q., Yan, L., Xu, B., Wang, X., Sun, X., Han, N., Tang, H. and Huang, F. (2021) Screening of the HBx Transactivation Domain Interacting Proteins and the Function of Interactor Pin1 in HBV Replication. Scientific Reports, 11, Article No. 14176. [Google Scholar] [CrossRef] [PubMed]
[4] 杨猛, 浦涧. 乙肝相关性肝癌发生机制的研究进展[J]. 右江医学, 2022, 50(8): 561-565.
[5] 张心怡, 张国梁, 张广林. 血清HBsAg和HBeAg定量检测评估恩替卡韦治疗乙型肝炎肝硬化合并原发性肝癌患者病毒应答的临床价值[J]. 实用医学杂志, 2023, 39(17): 2241-2247.
[6] 鲜林峰, 方乐天, 刘文斌, 赵沛, 陈一凡, 曹广文. 原发性肝癌流行现状、主要发病机制及防控策略[J]. 中国癌症防治杂志, 2022, 14(3): 320-328.
[7] Deng, Y., Du, Y., Zhang, Q., Han, X. and Cao, G. (2014) Human Cytidine Deaminases Facilitate Hepatitis B Virus Evolution and Link Inflammation and Hepatocellular Carcinoma. Cancer Letters, 343, 161-171. [Google Scholar] [CrossRef] [PubMed]
[8] 关健. 从法律和伦理角度看禁止死囚作为器官移植供体的意义和限制[J]. 中国医学伦理学, 2019(4): 479.
[9] 李彦南, 刘瑞宝. 肝癌介入与免疫联合治疗的机制与进展[J]. 现代肿瘤医学, 2022, 30(14): 2658-2661.
[10] 倪佳涛, 车斯尧. 原发性肝癌局部治疗的研究进展[J]. 中国肿瘤外科杂志, 2023, 15(5): 517-520.
[11] 史瑶平, 翟博. 肝癌局部治疗——消融或切除? [J]. 临床肝胆病杂志, 2021, 37(3): 506-509.
[12] Hsu, C.H., Hsu, H.C., Chen, H.L., Gao, M., Yeh, P.Y., Chen, P.J. and Cheng, A.L. (2004) Dox-orubicin Activates Hepatitis B Virus (HBV) Replication in HBV-Harboring Hepatoblastoma Cells. A Possible Novel Mechanism of HBV Reactivation in HBV Carriers Receiving Systemic Chemotherapy. Anticancer Research, 24, 3035-3040.
[13] Peng, J.W., Lin, G.N., Xiao, J.J. and Jiang, X.M. (2012) Hepatitis B Virus Reactivation in Hepatocel-lular Carcinoma Patients Undergoing Transcatheter Arterial Chemoembolization Therapy. Asia-Pacific Journal of Clinical Oncology, 8, 356-361. [Google Scholar] [CrossRef] [PubMed]
[14] 金烁. 恩替卡韦与乙肝表面抗原阳性合并肝癌切除术对病毒抑制的协同作用[D]: [硕士学位论文]. 长春: 吉林大学, 2015.
[15] Schiff, E.R., Lee, S.S., Chao, Y.C., Kew Yoon, S., Bessone, F., Wu, S.S., Kryczka, W., Lurie, Y., Gadano, A., Kitis, G., Beebe, S., Xu, D., Tang, H. and Iloeje, U. (2011) Long-Term Treatment with Entecavir Induces Reversal of Advanced Fibrosis or Cir-rhosis in Patients with Chronic Hepatitis B. Clinical Gastroenterology and Hepatology, 9, 274-276.E1. [Google Scholar] [CrossRef] [PubMed]
[16] 王忠, 刘启榆, 杨伟, 周西, 范丹丹, 鲜明凤. 介入治疗联合抗病毒治疗乙肝相关肝癌的疗效分析[J]. 中华肿瘤防治杂志, 2016, 23(s1): 158-159.
[17] 张健珍, 张春兰, 曾春燕, 杨慧勤, 孟玉. 核苷(酸)类似物在乙型肝炎相关原发性肝癌介入栓塞化疗中的作用[J]. 中国肿瘤临床, 2016, 43(22): 1002-1006.
[18] 龚鹏飞. 抗病毒治疗在肝癌介入围手术期及二期手术疗效观察[D]: [硕士学位论文]. 深圳: 南华大学, 2017.
[19] Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I.M., Washington, M.K., Germanidis, G., Flaherty, J.F., Aguilar Schall, R., Bornstein, J.D., Kitrinos, K.M., Subramanian, G.M., McHutchison, J.G. and Heathcote, E.J. (2013) Regression of Cirrhosis during Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B: A 5-Year Open-Label Follow-Up Study. The Lancet, 381, 468-475. [Google Scholar] [CrossRef] 
[20] 姜晓青, 解曼, 张群, 孔心涓, 饶伟. 替诺福韦单一用药预防肝移植术后乙肝复发的疗效分析[J]. 实用器官移植电子杂志, 2021, 9(2): 139-145.
[21] 张雪梅. 替诺福韦与恩替卡韦治疗慢性乙型肝炎初治患者的效果比较[J]. 临床合理用药杂志, 2023, 16(2): 83-85.
[22] Kim, S.U., Chen, M.B., Wang, H., Zheng, Q.H., Zheng, X.W., Fan, J.N., Ding, Y.L. and Niu, J.L. (2019) Comparative Efficacy of Tenofovir and Entecavir in Nucleos(t)ide Analogue-Naive Chronic Hepatitis B: A Systematic Review and Meta-Analysis. PLOS ONE, 14, e0224773. [Google Scholar] [CrossRef] [PubMed]